AlphaMark Advisors’s CureVac CVAC Stock Holding History

AlphaMark Advisors’s Portfolio CVAC Stock Details CVAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-125	Closed	-$7K	–	580
2021 Q3	$7K	Sell	125 -75	-38%	-$4.52K	﹤0.01%	434
2021 Q2	$15K	Sell	200 -125	-38%	-$12.5K	0.01%	356
2021 Q1	$30K	Buy	+325	New	+$31.5K	0.01%	278

Other funds holding CVAC

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

AlphaMark Advisors's CVAC Position: Q4 2021 in Review

AlphaMark Advisors sold out of CureVac (CVAC) in Q4 2021, closing a stake of 125 shares — an estimated $7K sold.

AlphaMark Advisors first reported a position in CVAC in Q1 2021 and held it in 3 quarters. The position peaked at $30K in Q1 2021. 103 funds tracked by Wall St. Rank hold CVAC as of Q4 2021.

AlphaMark Advisors reported no remaining CureVac position as of Q4 2021 after selling out during the quarter.
AlphaMark Advisors sold 125 CureVac shares in Q4 2021, an estimated $7K.
AlphaMark Advisors first reported a position in CureVac in Q1 2021 and held it in 3 quarters.
AlphaMark Advisors's CureVac position peaked at $30K in Q1 2021.
103 funds tracked by Wall St. Rank held CureVac as of Q4 2021.

Based on AlphaMark Advisors's 13F filing for Q4 2021, filed 9 Feb 2022.